Abstract
Abstract:The World Health Organization Fracture Risk Assessment Tool (FRAX™) and the National Osteoporosis Foundation’s (NOF) Clinician’s Guide to Prevention and Treatment of Osteoporosis are helpful clinical tools in the management of osteoporosis. Appropriate use of these tools requires a clear understanding of their limitations as well as their benefits. Good clinical judgment should be the ultimate determinant of treatment decisions. We anticipate that further refinements to FRAX™ and subsequent updates of the NOF guide will improve their clinical utility.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1.US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD, US Department of Health and Human Services, Office of the Surgeon General, 2004.US Department of Health and Human ServicesBone Health and Osteoporosis: A Report of the Surgeon General.Rockville, MDUS Department of Health and Human Services, Office of the Surgeon General20042.Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785–795.KlibanskiA]]Adams-CampbellL]]BassfordT&etal;Osteoporosis prevention, diagnosis, and therapy.JAMA2001285785-7953.National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC, National Osteoporosis Foundation, 2008. Available at: http://www.nof.org/professionals/Clinicians_Guide.htm. Accessed July 10, 2008.4.World Health Organization. WHO fracture risk assessment tool. Available at: http://www.shef.ac.uk/FRAX/. Accessed July 10, 2008.5.Dawson-Hughes B, Tosteson AN, Melton LJ III, et al; National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008;19:449–458.Dawson-HughesB]]TostesonAN]]MeltonLJIII&etal;National Osteoporosis Foundation Guide CommitteeImplications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.Osteoporos Int200819449-4586.Tosteson AN, Melton LJ III, Dawson-Hughes B, et al; National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008;19:437–447.TostesonAN]]MeltonLJIII]]Dawson-HughesB&etal;National Osteoporosis Foundation Guide CommitteeCost-effective osteoporosis treatment thresholds: the United States perspective.Osteoporos Int200819437-447
